High serum coenzyme Q10, positively correlated with age, selenium and cholesterol, in Inuit of Greenland. A pilot study

BioFactors ◽  
1999 ◽  
Vol 9 (2-4) ◽  
pp. 319-323 ◽  
Author(s):  
H. S. Pedersen ◽  
S. A. Mortensen ◽  
M. Rohde ◽  
Y. Deguchi ◽  
G. Mulvad ◽  
...  
Keyword(s):  
Pilot Study ◽  
Coenzyme Q10 ◽  
High Serum

The reduced form of coenzyme Q10 improves glycemic control in patients with type 2 diabetes: An open label pilot study

BioFactors ◽  
2012 ◽  
Vol 38 (6) ◽  
pp. 416-421 ◽  
Author(s):  
Morito Mezawa ◽  
Minoru Takemoto ◽  
Shunichiro Onishi ◽  
Ryoichi Ishibashi ◽  
Takahiro Ishikawa ◽  
...  
Keyword(s):  
Type 2 Diabetes ◽  
Pilot Study ◽  
Glycemic Control ◽  
Coenzyme Q10 ◽  
Reduced Form ◽  
Open Label

scholarly journals P026. Pilot study on the use of coenzyme Q10 in a group of patients with episodic migraine without aura

2015 ◽  
Vol 16 (S1) ◽  
Author(s):  
Giorgio Dalla Volta ◽  
Daniela Carli ◽  
Paola Zavarise ◽  
Gaelle Ngonga ◽  
Stefano Vollaro
Keyword(s):  
Pilot Study ◽  
Coenzyme Q10 ◽  
Migraine Without Aura ◽  
Episodic Migraine

scholarly journals Dietary supplementation of coenzyme Q10 plus multivitamins to hamper the ROS mediated cisplatin ototoxicity in humans: A pilot study

Heliyon ◽  
2017 ◽  
Vol 3 (2) ◽  
pp. e00251 ◽  
Author(s):  
Felice Scasso ◽  
Andrea Elio Sprio ◽  
Luciano Canobbio ◽  
Chiara Scanarotti ◽  
Giorgio Manini ◽  
...  
Keyword(s):  
Pilot Study ◽  
Coenzyme Q10 ◽  
Dietary Supplementation

A pilot study of liposomal irinotecan plus 5-FU/LV combined with paricalcitol in patients with advanced pancreatic cancer progressed on gemcitabine-based therapy.

2020 ◽  
Vol 38 (4_suppl) ◽  
pp. TPS793-TPS793
Author(s):  
Patrick Grierson ◽  
Andrea Wang-Gillam ◽  
Haeseong Park ◽  
Katrina Pedersen ◽  
Benjamin R. Tan ◽  
...  
Keyword(s):  
Vitamin D ◽  
Pilot Study ◽  
Tumor Microenvironment ◽  
Advanced Pancreatic Cancer ◽  
Primary Objective ◽  
High Serum ◽  
Ductal Adenocarcinoma ◽  
Combination Regimen ◽  
Second Line ◽  
Liposomal Irinotecan

TPS793 Background: Pancreatic ductal adenocarcinoma (PDAC) is predicted to be the second leading cause of cancer-related death by 2030, and is characterized by resistance to chemo- and radiotherapy and a highly fibrotic tumor microenvironment. Front-line therapies for advanced PDAC include FOLFIRINOX and gemcitabine/nab-paclitaxel with median overall survival ranging from 8.5 to 11 months. After progression on gemcitabine-containing therapy, 5-FU/LV/liposomal irinotecan is a standard second-line option, however outcomes are still poor. Retrospective studies demonstrate superior survival of advanced PDAC in patients with high serum levels of 25(OH) vitamin D. Notably, the PDAC tumor microenvironment is enriched in cancer-associated fibroblasts that favorably respond to vitamin D, prolonging survival in combination with chemotherapy in mouse models. Furthermore, vitamin D suppresses catabolism of irinotecan in gastrointestinal cancer cells, potentiating its efficacy. Therefore, we are conducing an investigator-initiated study of 5FU/LV/liposomal irinotecan with paricalcitol as second-line therapy in advanced PDAC. Methods: This is a pilot study of 5FU/LV/liposomal irinotecan combined with paricalcitol in patients with advanced PDAC progressed on gemcitabine-based therapy. All patients receive liposomal irinotecan, LV, 5-FU and paricalcitol. Liposomal irinotecan is given at 70 mg/m2 IV over 90 minutes, LV at 400 mg/m2 IV over 30 minutes, and 5-FU at 2400 mg/m2 continuous IV infusion over 46 hours, on Day 1 of each 14-day cycle. Paricalcitol IV infusion will precede the above, given according to assigned cohort (75 mcg weekly or 7 mcg/kg weekly). The primary objective of this study is to determine the tolerability between two different dose levels of paricalcitol added to the combination regimen of 5-FU/LV/liposomal irinotecan in patients with advanced PDAC. Secondary objectives are measures of efficacy (ORR, PFS, OS, CA19-9 biochemical response rate). Clinical trial information: NCT03883919.

Abstract W MP78: Intravascular Volume Delpetion in Hypertensive ED Stroke Patients

Stroke ◽  
2015 ◽  
Vol 46 (suppl_1) ◽  
Author(s):  
Christopher Lewandowski ◽  
Joseph Miller ◽  
Lauren Rodriquez ◽  
Julian Suszanski ◽  
Jessica Levely
Keyword(s):  
Pilot Study ◽  
Volume Expansion ◽  
Clinical Information ◽  
High Serum ◽  
Volume Status ◽  
Stroke Patients ◽  
Volume Depletion ◽  
Clinical Indicators ◽  
Laboratory Markers ◽  
The Mean

Objective: The hypertensive response in acute stroke may mask patients who could be volume depleted. Our objective was to determine the incidence of stroke patients that are volume depleted despite hypertension. This is a pilot study using sonographic markers of volume status as compared to common clinical indicators of volume status. Methods: This was a prospective cohort study of suspected ischemic stroke patients with a NIHSS ≥ 4 and symptoms onset < 24 hours. Exclusion criteria were pregnancy, age < 18, or ICH. Trained investigators performed a sonographic assessment of volume status. An IVC collapsibility index (IVC-CI) > 50% was used to define volume depletion. Investigators collected demographic and clinical information, and laboratory markers of dehydration (elevated blood urea nitrogen to creatinine ratio, hemoconcentration or high serum osmolality). A standardized questionnaire was given to treating clinicians who were blinded to the IVC-CI. They indicated their assessment of the patient's volume status. The analysis excluded subjects ultimately diagnosed with a stroke mimic. Analysis incorporated descriptive and regression statistics using SAS 9.3. The local IRB approved the study. Results: 23 subjects were enrolled, 4 had stroke mimics and were excluded from analysis. Mimics consisted of psychogenic disorders and myelopathy. The mean age was 64 years, 89% were Black, 68% female, and 95% had preexisting HTN. The mean NIHSS was 9.2, the mean time from symptom onset 309 minutes and the mean presenting SBP 170 ± 31 mmHg. 68% of subjects had a cortical infarct on MRI and the remaining had lacunar infarcts. The mean IVC-CI was 70 ± 21% and 84% (95% CI 68 - 100%) of subjects had IVC-CI > 50%. Laboratory markers of dehydration were present in 5% of subjects. Treating physicians classified 29% as subjects as hypovolemic. There was no correlation between IVC-CI and SBP, NIHSS, infarct location or laboratory markers of dehydration (r = 0.04 - 0.29, p > 0.23). Conclusions: This pilot study suggests that despite being hypertensive, the majority of ED stroke patients have US indications of volume depletion and may be able to tolerate volume expansion. Future studies may identify which patients have improvement in cerebral perfusion with volume expansion.

The relationship between retinol-binding protein 4 and apolipoprotein B-containing lipoproteins is attenuated in patients with very high serum triglycerides: A pilot study

HORMONES ◽  
2016 ◽  
Vol 15 (1) ◽  
pp. 99-105
Author(s):  
Georgios A. Christou ◽  
Constantinos C. Tellis ◽  
Moses S. Elisaf ◽  
Alexandras D. Tselepis ◽  
Dimitrios N. Kiortsis
Keyword(s):  
Pilot Study ◽  
Apolipoprotein B ◽  
Binding Protein ◽  
High Serum ◽  
Retinol Binding Protein ◽  
Serum Triglycerides ◽  
Retinol Binding Protein 4 ◽  
The Relationship ◽  
Very High

scholarly journals Pilot study of safety and efficacy of polyprenols in combination with coenzyme Q10 in patients with statin-induced myopathy

Medicina ◽  
2016 ◽  
Vol 52 (3) ◽  
pp. 171-179 ◽  
Author(s):  
Gustavs Latkovskis ◽  
Vita Saripo ◽  
Emma Sokolova ◽  
Dana Upite ◽  
Ilona Vanaga ◽  
...  
Keyword(s):  
Pilot Study ◽  
Coenzyme Q10 ◽  
Safety And Efficacy

scholarly journals AB0952 COENZYME Q10, TRYPTOPHAN AND MAGNESIUM: A NUTRITIONAL SUPPLEMENT IN THE TREATMENT OF FIBROMYALGIA SYMPTOMS

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 1773.1-1774
Author(s):  
A. Gomez-Centeno ◽  
M. Ramentol ◽  
M. J. Gonzalez ◽  
C. Alegre
Keyword(s):  
Pilot Study ◽  
Adverse Events ◽  
Coenzyme Q10 ◽  
Group Development ◽  
Placebo Treatment ◽  
Nutritional Supplement ◽  
Physical Symptoms ◽  
Full Time ◽  
Index Of Severity ◽  
Depressive Episodes

Background:Fibromyalgia syndrome (FMS) is a multidimensional chronic disorder characterized by widespread musculoskeletal pain, fatigue, sleep disturbances, cognitive dysfunction, depressive episodes, and anxiety [1]. Management of FMS remains challenging and treatment strategies are required to be multidisciplinary. Among nonpharmacological therapies, nutrition is a promising tool, since oxidative stress and/or an imbalance of nutritional components have demonstrated to play a critical role in the pathophysiology of FMS [2,3].Objectives:We conducted a pilot study (FATMIA Study) to investigate the efficacy and tolerability of a dietary supplementation (NSC) containing coenzyme Q10, magnesium and tryptophan in FMS patients.Methods:This was a prospective, double-blind, placebo-controlled, two-period pilot study conducted between March 2017-October 2017. All patients underwent two 3-month treatments with NSC and placebo, with a 1-month washout period in between. To evaluate the most prevalent clinical manifestations of FMS, the Combined Index of Severity of Fibromyalgia questionnaire (ICAF) [4] was used. A sample of 23 patients aged from 18 to 80 years, with a formal diagnosis of fibromyalgia of at least two years, was included in the study.Results:Twenty patients completed the study, while three (13.0%) dropped out because they failed to attend all clinical visits (n=2) or presented an adverse event (n=1). Participant demographics are presented in Table 1. All participants were female with a mean age of 51.9 (7.2) years. Depression and anxiety were reported in 65.0% (13/20) and 30.0% (6/20) of cases, respectively. All patients were under pharmacological treatment for FMS symptoms. The most commonly reported medications were paracetamol (60.0%, 12/20), selective serotonin reuptake inhibitors (45.0%, 9/20), and tramadol (40.0%, 8/20). Physical symptoms such as fatigue, functional capacity, pain and sleep quality improved at the end of the study treatment, whereas they mainly declined after placebo treatment. However, no statistically significant differences were found among the studied variables. Total ICAF score improved after NSC treatment, and declined after placebo treatment. NSC treatment was well tolerated, with a low incidence of adverse events (5.0%, 1/20).Table 1.Patient demographicsParameterValueAge, years [mean (SD]51.9 (7.2)Sex (F/M)20/0Weight, kg [mean (SD]69.3 (13.1)Height, cm [mean (SD]160.4 (6.5)Years since first FMS diagnosis [mean (SD)]7.7 (6.3)Occupational status, n (%) Working full-time/part-time10 (50.0) At home3 (15.0) Not working/receiving pension5 (25.0) Retired or unemployed2 (10.0)Smoking patients, n (%)8 (40.0)Patients on alcohol consumption, n (%)0 (0.0)Patients on physical activity, n (%)2 (10.0)F/M: female/maleConclusion:The results of this study constitute the first investigation of the effect of a nutritional supplement containing CoQ10, magnesium and tryptophan on FMS. Although the results should be confirmed in larger studies, they suggest that NSC treatment for 3 months, in addition to pharmacological therapy, may be of interest in the management of FMS. This treatment appeared to primarily improve physical symptoms, such as fatigue and pain, with low risk of adverse events.References:[1]Macfarlane GJ, Kronisch C, Dean L, Atzeni F, Häuser W, Fluss E. EULAR revised recommendations for the management of fibromyalgia. Ann Rheum Dis. 2016;76:1–11.[2]Cordero MD. Estrés oxidativo en la fibromialgia: fisiopatología e implicaciones clínicas. Reumatol Clin. 2011;7:281-3.[3]Bjørklund G, Dadar M, Chirumbolo S, Aaseth J. Fibromyalgia and nutrition: Therapeutic possibilities? Biomed Pharmacother. 2018;103:531-538.[4]Vallejo MA, Rivera J, Esteve-Vives J. ICAF Group. Development of a self-reporting tool to obtain a Combined Index of Severity of Fibromyalgia (ICAF). Health Qual Life Outcomes. 2010;8:2.Disclosure of Interests:None declared

Sign in / Sign up

Export Citation Format

Share Document